ES2382715T3 - Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa - Google Patents

Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa Download PDF

Info

Publication number
ES2382715T3
ES2382715T3 ES08737621T ES08737621T ES2382715T3 ES 2382715 T3 ES2382715 T3 ES 2382715T3 ES 08737621 T ES08737621 T ES 08737621T ES 08737621 T ES08737621 T ES 08737621T ES 2382715 T3 ES2382715 T3 ES 2382715T3
Authority
ES
Spain
Prior art keywords
heteroaryl
aryl
alkyl
heterocyclyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08737621T
Other languages
English (en)
Spanish (es)
Inventor
Sonali Rudra
Nidhi; BAREGAMA Lalit Kumar GUPTA
Ritu; KHAIRNAR Vinayak Vasantrao AGARWAL
Mandadapu Raghu; PALLE Venkata RAMAIAH
Sarala; KONDASKAR Atul BALACHANDRAN
Manohar; RAY Abhijit SALLA
Sunanda G.; VIJAYKRISHNAN DASTIDAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Application granted granted Critical
Publication of ES2382715T3 publication Critical patent/ES2382715T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES08737621T 2007-03-14 2008-03-14 Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa Active ES2382715T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INDE05502007 2007-03-14
IN550DE2007 2007-03-14
PCT/IB2008/050943 WO2008111010A1 (en) 2007-03-14 2008-03-14 Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
ES2382715T3 true ES2382715T3 (es) 2012-06-12

Family

ID=39575541

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08737621T Active ES2382715T3 (es) 2007-03-14 2008-03-14 Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa

Country Status (21)

Country Link
US (1) US8420666B2 (cg-RX-API-DMAC7.html)
EP (1) EP2124944B1 (cg-RX-API-DMAC7.html)
JP (1) JP5671236B2 (cg-RX-API-DMAC7.html)
KR (1) KR101568884B1 (cg-RX-API-DMAC7.html)
CN (2) CN103497185A (cg-RX-API-DMAC7.html)
AP (1) AP2453A (cg-RX-API-DMAC7.html)
AT (1) ATE545417T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008224541B2 (cg-RX-API-DMAC7.html)
CA (1) CA2680625C (cg-RX-API-DMAC7.html)
CY (1) CY1112805T1 (cg-RX-API-DMAC7.html)
DK (1) DK2124944T3 (cg-RX-API-DMAC7.html)
EA (1) EA018670B9 (cg-RX-API-DMAC7.html)
ES (1) ES2382715T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120361T1 (cg-RX-API-DMAC7.html)
MX (1) MX2009009793A (cg-RX-API-DMAC7.html)
NZ (1) NZ579645A (cg-RX-API-DMAC7.html)
PL (1) PL2124944T3 (cg-RX-API-DMAC7.html)
PT (1) PT2124944E (cg-RX-API-DMAC7.html)
SI (1) SI2124944T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008111010A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906418B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031838A1 (en) * 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
RU2451676C2 (ru) * 2006-08-16 2012-05-27 Ф.Хоффманн-Ля Рош Аг Ненуклеозидные ингибиторы обратной транскриптазы
EP2346867A1 (en) * 2008-09-19 2011-07-27 Ranbaxy Laboratories Limited Phosphodiestarase inhibitors
CA2783236C (en) 2009-12-08 2020-03-10 Vanderbilt University Improved methods and compositions for vein harvest and autografting
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
EA037544B1 (ru) * 2017-04-04 2021-04-12 Х. Лундбекк А/С ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
EP3723807B1 (en) * 2017-12-14 2021-10-20 H. Lundbeck A/S Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
TW201927784A (zh) * 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
CN113200997B (zh) * 2021-05-07 2023-10-03 上海合全医药有限公司 2,5-二氧杂-8-氮杂螺[3.5]壬烷及其盐的合成方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047518A (en) 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
NL128816C (cg-RX-API-DMAC7.html) 1965-04-22
GB1158492A (en) * 1966-02-09 1969-07-16 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3937838A (en) * 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
US3639434A (en) * 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
US3780177A (en) * 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
CH540244A (de) * 1967-11-17 1973-08-15 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US3700681A (en) * 1971-02-16 1972-10-24 Pfizer 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
US3947478A (en) 1972-01-12 1976-03-30 Akzona Incorporated Alkylated 3,20-diketo-Δ4 -steroids of the pregnane series
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US3992534A (en) 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
SE378109B (cg-RX-API-DMAC7.html) * 1972-05-19 1975-08-18 Bofors Ab
SE378110B (cg-RX-API-DMAC7.html) * 1972-05-19 1975-08-18 Bofors Ab
FR2231374B1 (cg-RX-API-DMAC7.html) 1973-05-30 1976-10-22 Jouveinal Sa
US4098804A (en) 1973-05-30 1978-07-04 Jouveinal S.A. Esters of 21-thiol prednisone and prednisolone
US4011258A (en) * 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
ZA744259B (en) 1973-08-17 1975-06-25 American Cyanamid Co Topical steroid
US3980778A (en) 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
NL7502252A (nl) 1974-02-27 1975-08-29 Pierrel Spa Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden.
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
US4076708A (en) 1976-12-22 1978-02-28 Schering Corporation Process for the preparation of 7α-halogeno-3-oxo-4-dehydro steroids and novel 7α-halogeno derivatives produced thereby
US4124707A (en) 1976-12-22 1978-11-07 Schering Corporation 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor
US4081541A (en) 1976-12-28 1978-03-28 Rorer Italiana S.P.A. Steroid derivatives
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
JPS6040439B2 (ja) * 1978-03-29 1985-09-11 大正製薬株式会社 ヒドロコルチゾン誘導体
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
DE3163871D1 (en) * 1980-07-09 1984-07-05 Draco Ab 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates
US4298604B1 (en) * 1980-10-06 1998-12-22 Schering Corp Clotrimazole-betamethasone dipropionate combination
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
DE3133081A1 (de) * 1981-08-18 1983-03-10 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue 6(alpha)-methylprednisolon-derivate, ihre herstellung und verwendung
US4472392A (en) * 1983-01-21 1984-09-18 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
CA1240708A (en) 1983-11-15 1988-08-16 Johannes K. Minderhoud Process for the preparation of hydrocarbons
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8425104D0 (en) * 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
CA1326662C (en) 1988-03-09 1994-02-01 Yutaka Mizushima 11.beta.,17.,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(e,e)-3,7,11-trimethyl-2,6,10-dodecatrienoate]
US5278156A (en) 1988-03-09 1994-01-11 Kuraray Co., Ltd. 11-beta, 17-alpha, 21-trihydroxy-1, 4-pregnadiene-3, 20 21-[(E-E)-3,7, 11-trimethyl-2,6,10-dodecatrienoate]
NZ234883A (en) 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
HU213401B (en) 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5254541A (en) 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indole/cyclodextrin complex
EP0542355A1 (en) 1991-11-15 1993-05-19 Merck Frosst Canada Inc. Amorphous (Quinolin-2-ylmethoxy)indoles as leukotriene antagonists
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
DZ1966A1 (fr) * 1995-02-06 2002-10-15 Astra Ab Combinaison pharmaceutique nouvelle.
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
SI0912558T1 (en) 1996-06-25 2003-10-31 Pfizer Inc. Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
PT1021413E (pt) * 1997-10-06 2003-10-31 Wyeth Corp A preparacao e utilizacao de acidos orto-sulfonamido heterociclicos biciclicos hidroxamicos como inibidores de metaloproteinases de matriz e de tace
IL135900A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
IL135714A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
JP2000198734A (ja) 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
EP1175419B1 (en) 1999-04-02 2003-05-28 Bristol-Myers Squibb Pharma Company Aryl sulfonyls as factor xa inhibitors
US20030176421A1 (en) * 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
DE10050994A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
MXPA03004652A (es) 2000-12-21 2003-09-05 Warner Lambert Co Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato.
WO2002051837A2 (en) 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
ATE327232T1 (de) 2000-12-22 2006-06-15 Wyeth Corp Heterozyklylalkylindole oder -azaindole als 5- hydroxytryptamine-6 liganden
MXPA02002749A (es) 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
US7429609B2 (en) * 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
CA2518398A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
CA2532403A1 (en) 2003-07-17 2005-02-03 James Arnold Ppar active compounds
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
RU2389729C2 (ru) 2003-12-22 2010-05-20 Мемори Фармасьютиклз Корпорейшн 1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение
CA2567977A1 (en) 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
DE602005011286D1 (en) 2004-07-05 2009-01-08 Astellas Pharma Inc Pyrazolopyridinderivate
WO2006016237A2 (en) 2004-08-04 2006-02-16 Ranbaxy Laboratories Limited Heterocyclic derivatives as anti-inflammatory agents
WO2006021848A1 (en) 2004-08-27 2006-03-02 Ranbaxy Laboratories Limited Anti-inflammatory agents
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006058120A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
WO2006056863A1 (en) 2004-11-23 2006-06-01 Ranbaxy Laboratories Limited Pyrido’2, 3-d!pyrimidines as anti-inflammatory agents
JP2008521831A (ja) 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
JP2008521829A (ja) 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
WO2006082492A1 (en) 2005-02-02 2006-08-10 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
CA2599662A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
EP1931668A2 (en) 2005-09-16 2008-06-18 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
US20090131431A1 (en) * 2005-09-29 2009-05-21 Christopher David Edlin Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
US20120004201A1 (en) * 2008-09-19 2012-01-05 Sonali Rudra Phosphodiestarase inhibitors

Also Published As

Publication number Publication date
AP2009004977A0 (en) 2009-10-31
ZA200906418B (en) 2010-05-26
HK1138758A1 (en) 2010-09-03
AP2453A (en) 2012-08-31
MX2009009793A (es) 2009-10-16
DK2124944T3 (da) 2012-04-23
KR101568884B1 (ko) 2015-11-12
ATE545417T1 (de) 2012-03-15
CA2680625A1 (en) 2008-09-18
NZ579645A (en) 2012-01-12
EA200970852A1 (ru) 2010-04-30
AU2008224541B2 (en) 2013-08-22
PL2124944T3 (pl) 2012-08-31
HRP20120361T1 (hr) 2012-05-31
EA018670B9 (ru) 2014-01-30
PT2124944E (pt) 2012-05-17
WO2008111010A1 (en) 2008-09-18
EP2124944B1 (en) 2012-02-15
EP2124944A1 (en) 2009-12-02
JP5671236B2 (ja) 2015-02-18
KR20090120505A (ko) 2009-11-24
JP2010521451A (ja) 2010-06-24
SI2124944T1 (sl) 2012-05-31
CN103497185A (zh) 2014-01-08
CN101801376A (zh) 2010-08-11
US20100292196A1 (en) 2010-11-18
AU2008224541A1 (en) 2008-09-18
US8420666B2 (en) 2013-04-16
EA018670B1 (ru) 2013-09-30
CY1112805T1 (el) 2016-02-10
CA2680625C (en) 2016-02-23

Similar Documents

Publication Publication Date Title
ES2382715T3 (es) Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa
AR075633A1 (es) Compuestos moduladores de jak quinasa y sus metodos de uso
AR081577A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
PH12017501655B1 (en) Morphinan derivative
ES2452299T3 (es) Compuestos heterocíclicos fungicidas
NO20092415L (no) Heteromonocyklisk forbindelse og anvendelse derav
AR076765A1 (es) Compuestos antivirales
ES2686501T3 (es) Pirazolo[1,5-a]piridinas sustituidas como inhibidores de la quinasa del receptor de tropomiosina (Trk)
NO20091012L (no) Kinazolinon- og isokinolinonacetamid derivater
UA107657C2 (uk) Похідні бензофурану
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
CO5580779A2 (es) Pirimidinonas como receptor 1 de la hormona concentradora de la melanina
AR094621A1 (es) Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
MX2010001609A (es) Proceso para producir derivados de piripiropeno e intermediarios para la produccion de los mismos.
ATE510829T1 (de) Neue verbindungen als adenosin-a1-rezeptor- antagonisten
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
ES2586527T3 (es) Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III
TW200639158A (en) New compounds with therapeutic effect
ECSP14013296A (es) Derivados de etinilo